Vascular complications of severe hyperhomocysteinemia in patients with homocystinuria due to cystathionine beta-synthase deficiency: effects of homocysteine-lowering therapy.
about
Structure of human cystathionine beta-synthase: a unique pyridoxal 5'-phosphate-dependent heme proteinActivation of mutant enzyme function in vivo by proteasome inhibitors and treatments that induce Hsp70Protein homeostasis disorders of key enzymes of amino acids metabolism: mutation-induced protein kinetic destabilization and new therapeutic strategies.Corrective effects of hepatotoxicity by hepatic Dyrk1a gene delivery in mice with intermediate hyperhomocysteinemia.New chemodosimetric reagents as ratiometric probes for cysteine and homocysteine and possible detection in living cells and in blood plasma.Homocysteine: an aetiological contributor to peripheral vascular arterial disease.Pharmacotherapy of hyperhomocysteinaemia in patients with thrombophilia.Testosterone and phosphodiesterase type-5 inhibitors: new strategy for preventing endothelial damage in internal and sexual medicine?Hyperhomocysteinemia attenuates angiogenesis through reduction of HIF-1α and PGC-1α levels in muscle fibers during hindlimb ischemiaFolate improves endothelial function in patients with coronary heart disease.Cystathionine β-synthase regulates endothelial function via protein S-sulfhydration.Biosynthesis of H2S is impaired in non-obese diabetic (NOD) mice.Mouse models of cystathionine beta-synthase deficiency reveal significant threshold effects of hyperhomocysteinemia.Cystathionine β-synthase-deficient mice thrive on a low-methionine diet.Guidelines for the diagnosis and management of cystathionine beta-synthase deficiency.Correction of cystathionine β-synthase deficiency in mice by treatment with proteasome inhibitors.Isolated remethylation disorders: do our treatments benefit patients?Homocysteine and hydrogen sulfide in epigenetic, metabolic and microbiota related renovascular hypertension.Cystathionine β-synthase deficiency: Of mice and men.Acute myocardial infarction in a young patient with hyperhomocysteinaemia.Smoking and atherosclerotic cardiovascular disease: part II: role of cigarette smoking in cardiovascular disease development.Role of hydrogen sulfide production in inhibitory action of L-cysteine on isolated porcine irides.Homocysteine and coronary heart disease: the importance of a distinction between low and high risk subjects.Isolated aortic root dilation in homocystinuria.Severe central nervous system thrombotic events in hemoglobin Sabine patient.Necessity of long-term alertness in levodopa-carbidopa intestinal gel infusion for PD patients.Thrombocytopaenia after aortic valve replacement with stented, stentless and sutureless bioprostheses.
P2860
Q24291509-F94E0B5E-9668-4A2E-ADD6-7CC21AE09182Q28472376-D0AE0ABF-0360-40B0-A6EB-D69688A75682Q30355120-0A5B9CFE-E31D-42D2-831F-54F64F4A9915Q33799086-DFF8BB42-8BF8-4834-8240-14F876539F8AQ34444106-A5F695E6-51AC-4720-871B-1A845EC8F0BEQ34881130-BE2898C5-9FB4-4C7B-884B-5586939706D4Q35000962-FEE0A244-302B-4DAC-AB05-50D376A17199Q35076387-7D0B75FA-C244-462C-83A8-DEDEABCA0342Q35105501-E37C0E3F-3EC9-4591-B1AD-65D00F1B0863Q35600457-4A18CFD3-DDB1-4C40-B445-E0A825A996DDQ36385381-DFCBC6D8-0976-437A-99D7-6D67CD8E5410Q36977469-29C2415D-B9FD-47B2-995B-265B9F56C205Q37123978-5148FB60-FF5D-4B70-A31A-14E0D176D82DQ37503715-B333F254-7FAC-47B3-BA99-C0444FBC3C8EQ37547501-AF6FC0E4-B956-491F-BC83-E6EFBF647B7DQ37615678-8E57C71A-D1C5-4B21-927C-FFB541D260E1Q37758544-51B7C886-2632-4631-A440-692A07C89DE7Q38948319-ABADB8DF-6CBB-4AAD-8205-70541EC0281EQ39352707-3504D952-87EA-4B63-B0EC-F7BDEE9E4901Q41837097-D0EFA6EA-5909-4EBB-A3BD-D530CE76D61DQ43061592-05ED9D40-E9B9-4BE6-B946-307B956612F2Q43070118-F9FF79D8-FD41-446D-8D44-3D3304343DF8Q44286470-8B0D420B-5BE2-4F93-8A0A-7B6111EC95A8Q49589041-43A2C756-78A0-41AA-A5A1-5100003CC93BQ51038184-7660EF49-C28B-4B08-B5FB-2D6952A97C50Q52844941-619AB51B-B4B4-40E9-9BA4-9A227156222AQ54489133-20D4D6D3-23A3-4D01-8A8E-E6BCA60CEA29
P2860
Vascular complications of severe hyperhomocysteinemia in patients with homocystinuria due to cystathionine beta-synthase deficiency: effects of homocysteine-lowering therapy.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Vascular complications of seve ...... homocysteine-lowering therapy.
@ast
Vascular complications of seve ...... homocysteine-lowering therapy.
@en
Vascular complications of seve ...... homocysteine-lowering therapy.
@nl
type
label
Vascular complications of seve ...... homocysteine-lowering therapy.
@ast
Vascular complications of seve ...... homocysteine-lowering therapy.
@en
Vascular complications of seve ...... homocysteine-lowering therapy.
@nl
prefLabel
Vascular complications of seve ...... homocysteine-lowering therapy.
@ast
Vascular complications of seve ...... homocysteine-lowering therapy.
@en
Vascular complications of seve ...... homocysteine-lowering therapy.
@nl
P2093
P356
P1476
Vascular complications of seve ...... homocysteine-lowering therapy.
@en
P2093
P304
P356
10.1055/S-2000-8100
P577
2000-01-01T00:00:00Z